Mary Kay Washington, MD, PhD, FASCP, FCAP, and Jaffer A. Ajani, MD, FASCO, offer their clinical insight and brief explanation of the new evidence-based “CAP-ASCP-ASCO HER2 Testing and Clinical Decision-making in Gastroesophageal Adenocarcinoma Guideline.”
CAP President Richard C. Friedberg, MD, PhD, FCAP, attended the Cancer Moonshot Task Force event at the White House. The CAP will participate in the Blood Profiling Atlas project which will seek to establish protocols for collecting and analyzing blood samples in cancer care.
CAP16 - The Pathologists' Meeting, will feature a record number of health care societies collaborating with over 1,300 College of American Pathologists members.
The College of American Pathologists (CAP) released on August 17, 2016, enhanced Laboratory Accreditation Program checklists, used in the accreditation inspection process to help laboratories meet the Centers for Medicare and Medicaid Services (CMS) requirements.
Leading pathologists will collaborate in Las Vegas to discuss the specialty's role in the promising area of immunotherapy, as well as several other health care issues at the annual meeting of the College of American Pathologists.
The CAP supports the introduction of HR 5721, which primarily improves the local coverage determination (LCD) process to help ensure open meetings, upfront disclosure, and reconsideration with options for appeal—all of which greatly affect patients, pathologists, and other physicians across the US.
The College of American Pathologists (CAP) , the leading organization of board-certified pathologists, serves patients, pathologists and the public by fostering and advocating excellence in pathology and laboratory medicine worldwide. This report summarizes that activity.
Clinicians and patients alike will benefit as the Pathology and Laboratory Quality Center (the Center) of the College of American Pathologists (CAP) releases a new evidence-based guideline that tackles the complexities of reporting findings from bone marrow specimens.
For National Breast Cancer Awareness Month, Dr. Jean Simpson, a breast pathologist, offers information to help patients become more informed about their options and treatment process.
September is National Prostate Health Month and expert pathologist Dr. Michael Misialek can fill you in on what you should know about prostate screening and how to talk to your doctor about next steps and treatment.
.The College of American Pathologists (CAP) released on July 28, 2015, enhanced Laboratory Accreditation Program checklists, used in the accreditation inspection process to help laboratories meet the CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS) requirements. The CMS REAPPROVED the CAP's accreditation program in April, deeming the CAP meets or exceeds Clinical Laboratory Improvement Amendments requirements.
Faced with a diagnosis of prostate cancer, men should “know the right questions to ask, understand their disease and fully engage in a two-way conversation with their doctor. Michael J. Misialek, MD, FCAP, offers tips for men to better understand a diagnosis of prostate cancer.
CAP Learning was recognized by the Association for Talent Development with an Excellence in Practice Award for its the Laboratory Medical Director Advanced Practical Pathology Program.
Dr. Jean Simpson, chair of the CAP Cancer Committee, offers four tips for women diagnosed with breast cancer following Sandra Lee's announcement to receive a double mastectomy as a result of a diagnosis of DCIS.
Today, the College of American Pathologists (CAP) and the Association of Directors of Anatomic and Surgical Pathology (ADASP) announced the joint release of a new evidence-based guideline to provide recommendations for secondary and timely reviews of surgical pathology and cytology cases to improve patient care. The guideline, “Interpretive Diagnostic Error Reduction in Surgical Pathology and Cytology,” has been posted as an Early Online Release publication on the Archives of Pathology & Laboratory Medicine website.
Dr. Gail Vance shares insights into genetic testing for breast and ovarian cancer in lieu of Angelina Jolie's recent announcement to have her ovaries removed. Dr. Vance is the Sutphin professor of Cancer Genetics and interim chairperson of the Department of Medical and Molecular Genetics at the Indiana University School of Medicine. As well, she is director of the Division of Diagnostic Genomics and the Indiana Familial Cancer Program, which provides genetic counseling, risk assessment, and genetic testing to individuals with an elevated risk for developing cancer.
Gary W. Procop, MD, FCAP, a pathologist and infectious disease expert, offers symptoms parents should watch for if they suspect their child has the measles. Dr. Procop also sheds light on the how pathologists diagnose measles and the tests used.
Today, the College of American Pathologists (CAP) and the National Society for Histotechnology (NSH) released the first evidence-based guideline to ensure patient safety through the uniform labeling of paraffin blocks and slides. The guideline, “Uniform Labeling of Blocks and Slides in Surgical Pathology,” is now available in the online edition of Archives of Pathology & Laboratory Medicine.
The CAP and Dr. Jean Simpson offer tips and questions for women who are diagnosed with breast cancer to better understand their diagnosis to make informed decisions about their health.
The CAP will offer educational resources during National Patient Safety Awareness Week (March 8-14) to help patients and their loved ones understand their pathology reports and diagnoses and engage with their physicians.
The College of American Pathologists (CAP), the American Society of Clinical Oncology’s (ASCO) ASCO University®, and the Association for Molecular Pathology (AMP) recently announced their partnership in the creation of the Molecular Oncology Tumor Board series, an online and user-driven resource designed to help cancer care providers with the interpretation and understanding of tumor molecular profiling tests and studies.
The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) are teaming to revise the evidence-based guideline, “Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors.” The updated guideline will include new recommendations for ALK testing by IHC, ALK-EGFR resistance, and a number of emerging target molecular targets which will include, but is not limited to, ROS1, MET, ERBB2, RET, NTRK1. Multiplexed "Next Generation Sequencing" multigene panels and the reassessment of immunohistochemistry will be reviewed. The role of rebiopsy and repeat analysis in the setting of post-treatment relapse, along with testing of blood samples for mutations in circulating tumor cells, cell free tumor DNA, or exosomes will be considered.
Active surveillance offers low-risk prostate cancer patients a means to avoid the potentially harmful side effects from treatment. Pathologists help determine patient eligibility for active surveillance and today a multi-specialty team published their recommendations for making such determinations in a special on-line posting from the Archives of Pathology & Laboratory Medicine.
New science in molecular and genetic testing for breast, colon, and prostate cancer, as well as leukemia, will be among the special features at the College of American Pathologists’ annual scientific and education meeting, CAP’14—THE Pathologists’ Meeting, Sept. 7-10 at the Hyatt Regency in Chicago.
CAP, APC, and API announce new graduate medical education clinical informatics curriculum -- Pathology Informatics Essentials for Residents (PIER) -- at the APC annual meeting on July 9, 2014. Curriculum meets ACGME milestone requirements.
The College of American Pathologists Foundation announced today that it has been selected to receive a grant of nearly $95,000 from the Robert wood Johnson Foundation (RWJF) to evaluate the impact of its See, Test & Treat cancer screening program.
Kimberly Allison, MD, FCAP, a pathologist and survivor of HER2 breast cancer, shares her story. She also offers patients questions to ask their physicians related to the into the evidence-based guideline for HER2 testing developed by the American Society of Clinical Oncology and the College of American Pathologists.